Product Details
Place of Origin: China
Brand Name: Sunshine
Certification: ISO,COA
Model Number: 82159-09-9
Payment & Shipping Terms
Minimum Order Quantity: Negotiation
Price: Negotiation
Packaging Details: Aluminum Foil Bag, Drum
Delivery Time: 7-15DAY
Payment Terms: L/C,D/A,D/P,T/T,Western Union,MoneyGram
Supply Ability: G,KG,TON
Appearance:: |
Deep Red Acicular Crystal |
CAS NO:: |
82159-09-9 |
Molecular Formula:: |
C15H13NO3S2 |
Molecular Weight:: |
319.39900 |
EINECS NO:: |
675-018-0 |
MDL NO:: |
MFCD00865484 |
Appearance:: |
Deep Red Acicular Crystal |
CAS NO:: |
82159-09-9 |
Molecular Formula:: |
C15H13NO3S2 |
Molecular Weight:: |
319.39900 |
EINECS NO:: |
675-018-0 |
MDL NO:: |
MFCD00865484 |
Product Description:
Product Name: Epalrestat CAS NO: 82159-09-9
Synonyms:
5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid;
2-[(5Z)-5-[(E)-2-methyl-3-phenylprop-2-enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]acetic acid;
(Z,E)-5-(2-methyl-3-phenyl-2-propenylidene)-4-oxo-2-thioxo-3-thiazolidineacetic acid;
Chemical & Physical Properties:
Appearance: Deep red acicular crystal
Assay :≥99.00%
Density: 1.43 g/cm3
Boiling Point: 516.8℃ at 760 mmHg
Melting Point: 210-217℃
Flash Point: 266.4℃
Refractive Index: 1.705
Storage Condition: Store in original container in a cool dark place
Safety Information:
RIDADR: 2811
WGK Germany: 3
RTECS : XJ5131855
Hazard Class: 6.1
Packing Group: II
Epalrestat is a carboxylic acid derivative and a noncompetitive and reversible aldose reductase inhibitor used for the treatment of diabetic neuropathy, which is one of the most common long-term complications in patients with diabetes mellitus. It reduces the accumulation of intracellular sorbitol which is believed to be the cause of diabetic neuropathy, retinopathy and nephropathy It is well tolerated, with the most commonly reported adverse effects being gastrointestinal issues such as nausea and vomiting, as well as increases in certain liver enzymes. Chemically, epalrestat is unusual in that it is a drug that contains a rhodanine group. Aldose reductase is the key enzyme in the polyol pathway whose enhanced activity is the basis of diabetic neuropathy. Aldose reductase inhibitors (ARI) target this enzyme. Out of the many ARIs developed, ranirestat and fidarestat are in the trial stage. Others have been discarded due to unacceptable adverse effects or weak efficacy. Epalrestat is the only ARI commercially available. It is easily absorbed into the neural tissue and inhibits the enzyme with minimum side effects.
If you are interested in our products or have any questions, please feel free to contact us!
Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.